Angiotech, Boston Scientific's registry results confirm safety of Taxus stent

By Lisa Kerner

Erie, Pa., March 14 - Angiotech Pharmaceuticals, Inc.'s corporate partner, Boston Scientific Corp., announced preliminary six-month results from its Arrive II registry, confirming the safety of the Taxus Express(2) coronary stent system.

Arrive II expands on the Arrive I registry by studying more than 5,000 enrolled patients across 53 sites in the United States, including patients with complex lesions, multiple stents and diabetes, according to a company news release.

Six-month findings demonstrated an overall Taxus-related major cardiac event rate of 3.6%; including cardiac death, 0.7%; myocardial infarction, 1.2%; and Taxus-related re-intervention of the target vessel, 2.5%.

Boston Scientific made the announcement at the i2 Summit held in conjunction with the annual American College of Cardiology Scientific Session in Atlanta.

The company acquired worldwide exclusive rights from Angiotech to use paclitaxel to coat its coronary stent products.

Vancouver, B.C.-based Angiotech Pharmaceuticals combines pharmaceutical compounds with medical devices and biomaterials to create novel solutions for poorly addressed disease states and improve surgical outcomes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.